首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   16769篇
  免费   1647篇
  国内免费   352篇
耳鼻咽喉   92篇
儿科学   290篇
妇产科学   468篇
基础医学   1092篇
口腔科学   622篇
临床医学   2325篇
内科学   2233篇
皮肤病学   352篇
神经病学   964篇
特种医学   1019篇
外国民族医学   3篇
外科学   1617篇
综合类   1607篇
一般理论   1篇
预防医学   1233篇
眼科学   148篇
药学   1948篇
  6篇
中国医学   2134篇
肿瘤学   614篇
  2024年   49篇
  2023年   456篇
  2022年   566篇
  2021年   905篇
  2020年   796篇
  2019年   865篇
  2018年   809篇
  2017年   762篇
  2016年   630篇
  2015年   667篇
  2014年   1799篇
  2013年   1670篇
  2012年   1077篇
  2011年   971篇
  2010年   808篇
  2009年   756篇
  2008年   774篇
  2007年   706篇
  2006年   661篇
  2005年   598篇
  2004年   485篇
  2003年   335篇
  2002年   309篇
  2001年   228篇
  2000年   162篇
  1999年   137篇
  1998年   123篇
  1997年   90篇
  1996年   81篇
  1995年   48篇
  1994年   64篇
  1993年   40篇
  1992年   40篇
  1991年   36篇
  1990年   41篇
  1989年   38篇
  1988年   28篇
  1987年   25篇
  1986年   14篇
  1985年   25篇
  1984年   18篇
  1983年   15篇
  1982年   10篇
  1981年   11篇
  1980年   7篇
  1979年   8篇
  1977年   6篇
  1975年   4篇
  1973年   4篇
  1971年   4篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.

Background

Treatment of advanced anal squamous cell cancer (SCC) is usually with the combination of cisplatin and 5-fluorouracil, which is associated with heterogeneous responses across patients and significant toxicity. We examined the safety and efficacy of a modified schedule, FOLFCIS (leucovorin, fluorouracil, and cisplatin), and performed an integrated clinical and genomic analysis of anal SCC.

Patients and Methods

We reviewed all patients with advanced anal SCC receiving first-line FOLFCIS chemotherapy – essentially a FOLFOX (leucovorin, fluorouracil, and oxaliplatin) schedule with cisplatin substituted for oxaliplatin – in our institution between 2007 and 2017, and performed deep sequencing to identify genomic markers of response and key genomic drivers.

Results

Fifty-three patients with advanced anal SCC (48 metastatic; 5 unresectable, locally advanced) received first-line FOLFCIS during this period; all were platinum-naive. The response rate was 48% (95% confidence interval [CI], 32.6%-63%). With a median follow-up of 41.6 months, progression-free survival and overall survival were 7.1 months (95% CI, 4.4-8.6 months) and 22.1 months (95% CI, 16.9-28.1 months), respectively. Among all patients with advanced anal SCC that underwent sequencing during the study period, the most frequent genomic alterations consisted of chromosome 3q amplification (51%) and mutations in PIK3CA (29%) and KMT2D (22%). No genomic alteration correlated with response to platinum-containing treatment. Although there were few cases, patients with human papillomavirus-negative anal SCC did not appear to benefit from FOLFCIS, and all harbored distinct genomic profiles with TP53, TERT promoter, and CDKN2A mutations.

Conclusions

FOLFCIS appears effective and safe as first-line chemotherapy in patients with advanced anal SCC and represents an alternative treatment option for these patients.  相似文献   
22.
Paediatric palliative care and neurodisability are two relatively new, evolving paediatric sub-specialities that have increasing relevance in the current paediatric landscape. For many people palliative care has been synonymous with end of life care, but in paediatrics it encompasses much more and is for all children with life-threatening or life-limiting conditions, from the point of diagnosis. This breadth of focus is demonstrated well through the interface between paediatric palliative care and paediatric neurodisability. In this article we explore this unique interface through the three domains of complex symptom management, advanced care planning and end of life care. We describe the practicalities involved in all three areas and highlight the importance of early referral and the process of “dual” or “parallel” planning. We cover in more depth the specific management of the symptoms: dystonia/abnormalities of muscle tone, seizures, pain, agitation, secretions, respiratory failure, and gut failure.  相似文献   
23.
24.
25.
26.
27.
28.
29.
30.
IntroductionDural puncture epidural (DPE) analgesia is a modification of conventional epidural analgesia that involves the intentional puncture of the dura with a spinal needle through the needle placed in the epidural space, without a medication being injected intrathecally. There have been contradictory findings regarding better analgesia and better block quality.MethodsA systematic literature search was done to identify randomized controlled trials (RCT) comparing DPE with epidural analgesia. The risk of bias was assessed with the Cochrane tool. Risk ratio and 95% confidence intervals were calculated.ResultsFive RCTs including 581 patients were identified. One RCT on caesarean section was excluded. Single studies suggested slightly better analgesia by finding a median time to achieve sufficient analgesia of two minutes less in the DPE group, a higher number of women having a pain score <10/100 at 20 min, a reduction in the number of epidural top-ups and better sacral spread. The studies did not show a difference between DPE and epidural analgesia for catheter replacement or manipulation rates, the incidence of intravascular placement or unilateral block.ConclusionThere is a lack of clear evidence on either the benefits or the risks of the DPE technique, such that a recommendation for or against its routine use is premature. Two of the three studies showing a beneficial effect of DPE came from the same institution and replication of the findings by other groups is warranted.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号